Current and emerging therapies for the treatment of osteoporosis

Jill Waalen
Department of Molecular and Experimental Medicine, The Scripps Research Institute, CA, USA

Abstract: Osteoporosis represents a weakening of bone tissue due to an imbalance in the dynamic processes of bone formation and bone resorption that are continually ongoing within bone tissue. Most currently available osteoporosis therapies are antiresorptive agents. Over the past decade, bisphosphonates, notably alendronate and risedronate, have become the dominant agents with newer bisphosphonates such as ibandronate and zoledronic acid following a trend of less frequent dosing regimens. Synthetic estrogen receptor modulators (SERMs) continue to be developed as drugs that maintain the bone-protective effects of estrogen while avoiding its associated adverse side effects. Currently available agents of this class include raloxifene, the only SERM available in the United States (US), and lasofoxifene and bazedoxifene, available in Europe. Calcitonin, usually administered as a nasal spray, completes the list of currently approved antiresorptive agents, while parathyroid hormone analogs represent the only anabolic agents currently approved in both the US and Europe. Strontium ranelate is an additional agent available in Europe but not the US that has both anabolic and antiresorptive activity. New agents expected to further expand therapeutic options include denosumab, a monoclonal antibody inhibitor of the resorptive enzyme cathepsin K, which is in the final stages of Food and Drug Administration approval. Other agents in preclinical development include those targeting specific molecules of the Wnt/β-catenin pathway involved in stimulating bone formation by osteoblast cells. This review discusses the use of currently available agents as well as highlighting emerging agents expected to bring significant changes to the approach to osteoporosis therapy in the near future.

Keywords: bone formation, bone resorption, antiresorptive agent, anabolic agent

Introduction

Bone is a dynamic tissue, undergoing a continual remodeling process involving a cycle of formation of new bone tissue and breakdown (resorption) of older bone tissue. In osteoporosis, the balance of these processes is tipped toward resorption, leading to weakening of bone tissue and increased risk of fracture. Pharmacotherapy for the prevention and treatment of osteoporosis has predominantly been based on agents that prevent resorption of bone. Most available agents are effective at increasing bone mineral density or preventing fractures of the vertebra. The majority also have effects on nonvertebral sites, including the hip.

Over the past decade, bisphosphonates have become the most commonly prescribed osteoporosis medication following the decline of the use of estrogen-based hormone therapy as a result of the United States (US) Women’s Health Initiative trial. Focus in hormone therapy has shifted to synthetic estrogen receptor modulators (SERMs)
designed to retain the positive effects of estrogen on bone while minimizing the negative effects of increasing risk of cardiovascular disease and cancer. Calcitonin hormone (another antiresorptive agent), parathyroid hormone (PTH) analogs (to date the only anabolic agent for osteoporosis treatment available in the US), and strontium ranelate (an agent with both anabolic and antiresorptive activity used widely in Europe, but not the US) complete the list of currently available treatment options.

New treatments in clinical trials include both new generations of currently available therapies and agents with novel mechanisms of action. New therapeutic strategies are also emerging from recent discoveries regarding the role of biologic pathways such as the Wnt/β-catenin pathway in regulating bone cell function. These strategies include more agents targeted to promote bone growth with the potential to be more effective in preventing fractures than current approaches.

**Disease prevalence and treatment guidelines**

Osteoporosis represents a condition of compromised bone strength predisposing a person to an increased risk of fracture. Bone strength depends on both bone quality and bone density. While bone density is relatively easily measured, by dual x-ray absorptiometry (DXA) and other modalities, there are few good measures of bone quality. Bone mineral density (BMD) has thus become the most common clinical measure of osteoporosis, although its relationship to risk of fracture is not strictly proportional.1,2

The World Health Organization (WHO) has defined osteoporosis as a BMD measurement of 2.5 standard deviations or more below the population mean BMD of sex-matched young adults, ie, a T-score of ≤−2.5.3 BMD is typically measured at the lumbar spine, femoral neck, and hip. A T-score of <−2.5 at any of those sites is diagnostic for osteoporosis. Osteopenia, or low bone mass, is defined as 1.5 to 2.5 standard deviations below the population mean. The occurrence of a nontraumatic fracture, regardless of BMD, is also considered by definition to be osteoporosis.

According to statistics compiled by the International Osteoporosis Foundation, more than 75 million people in the United States, Europe, and Japan have osteoporosis with an additional 70 million persons likely affected in China.4 The US National Osteoporosis Foundation (NOF) has estimated that 10 million people have osteoporosis in the US alone with another 34 million having osteopenia.5 As a result, lifetime risk of fracture for whites over the age of 50 years in the US is estimated to be 53% for females and 21% for males.5 Fractures are costly to the individual in terms of morbidity – leading to chronic pain, disability, and loss of independence – and increased mortality. Costs to society are also high; according to NOF, two million osteoporotic fractures occur in the US per year, costing $19 billion/year in treatment costs.5 By the year 2015, these numbers are expected to increase to three million fractures at a cost of more than $25 billion/year. Nine million osteoporotic fractures are estimated to occur annually worldwide.4

An international consensus regarding who to screen and treat does not currently exist.6 In the US, BMD screening is recommended by most organizations for all women aged 65 years and older, all men aged 70 years and older, and women and men aged 50 to 70 at high risk for the disease.7 Risk calculators, such as WHO’s online FRAX® calculators (World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK) can determine an individual’s specific risk of fracture over the next 10 years based on country of residence and by inputting femoral neck BMD along with age, sex, height, weight, history of personal or parental fracture, smoking and drinking status, history of rheumatoid arthritis, use of glucocorticoids, or secondary osteoporosis.8

Guidelines from NOF and other organizations in the US call for initiation of treatment in the following patients:9

1. Patients with hip or vertebral fractures
2. Patients with BMD T-scores ≤−2.5 at the femoral neck, total hip, or spine by DXA
3. Postmenopausal women or men ≥50 years old with low bone mass (T-score between −1 and −2.5) at the femoral neck, total hip, or spine AND:
   a. 10 year hip fracture probability ≥3% OR
   b. 10 year all major osteoporosis-related fracture probability of ≥20% based on the US-adapted WHO absolute fracture risk model

Osteoporosis is largely under-treated. In one study in the US, it was shown that only 26% of white women at high risk for fracture were receiving osteoporosis therapy, with the rate being less than 3% among men and black women with the same risk.1 Low rates of adherence to osteoporosis medications contribute to under-treatment of the disease, with most studies estimating that 50% or less of patients with a prescription for osteoporosis medication actually take the medication as prescribed, regardless of the type of medication or frequency of dosing.10 Improved adherence thus continues to be a goal in osteoporosis therapy.
Bone biology
Pharmacologic therapies for osteoporosis have been targeted to a number of different molecular processes involved in the bone remodeling cycle. Bone tissue is specialized connective tissue composed of cells, organic bone matrix, and inorganic calcified crystals. In addition to its mechanical function, bone plays a role in metabolic functions, such as serving as the primary storage site for calcium, phosphate, and other minerals. Thus, bone remodeling is not only altered by mechanical stresses, but also responds to a number of systemic hormones that regulate calcium homeostasis.

There are three primary cell types in bone, two of which, osteoblasts and osteoclasts, are located at the surface of the bone matrix. Osteocytes, which are derived from osteoblasts, are embedded in the bone matrix (Figure 1). During the continual bone remodeling cycle, osteoclasts demineralize and resorb old bone, and osteoblasts deposit new bone to maintain a bone mass that adequately responds to the stresses placed on the skeleton.

Osteoblasts actively produce osteoid, the organic component of the bone matrix, composed mainly of Type I collagen fibers along with a mixture of proteoglycans, phosphoproteins, phospholipids, hyaluronic acid, and glycoproteins (Figure 1).11,12 Two of these glycoproteins, osteocalcin and sialoprotein, are bone-specific and have a high affinity for calcium. The inorganic component of the bone matrix is made up of calcium and phosphorus deposited along the osteoid scaffolding primarily in the form of hydroxyapatite crystals. Osteoclasts resorb the matrix by secreting hydrochloric acid, which dissolves calcium phosphate, and enzymes such as collagenases and other proteases. The most important of the proteases is cathepsin K, which degrades the organic matrix including Type I collagen.11

Normally the processes of bone formation and bone resorption are tightly balanced. Disturbance of this balance can compromise bone density, strength, and microarchitecture. Most often this occurs due to increased osteoclast activity, leading to increased bone resorption and diminished bone density. In post-menopausal women, increased osteoclast activity results from the loss of estrogen; with the largest decrease in BMD occurring within five years of the beginning of menopause.13

Systemic calcium homeostasis is under the control of three hormones with direct effects on bone tissue: vitamin D, calcitonin, and PTH. Activated vitamin D3 stimulates intestinal absorption of calcium. In bone, vitamin D3 binds to receptors on osteoblasts to increase release of osteocalcin and another glycoprotein, osteopontin, to facilitate mineralization.14 PTH is released from the
parathorid glands in response to low calcium. Continuous high PTH levels act to mobilize calcium and phosphorus by stimulating resorption by osteoclasts. High serum calcium feeds back to inhibit PTH release. Calcitonin is released from the thyroid gland in response to high serum calcium levels. It binds to receptors on osteoclasts and directly inhibits their activity, leading to reduced resorption and lower calcium levels.

Estrogen is another systemic hormone with direct effects on bone and playing an important role in osteoporosis. Recently it has been shown that estrogen acts through the estrogen receptor α (ERα) on osteoclasts to facilitate the expression of the FasL gene and induce apoptosis of osteoclasts, thereby controlling their lifespan.

Within bone tissue, resorption is controlled by a system of three key proteins: RANK (receptor activator of nuclear factor kappa beta), its ligand RANKL (receptor-activator of nuclear factor kappa beta ligand), and a decoy receptor OPG (osteoprotegerin) (Figure 1). Binding of RANKL, a membrane-bound protein produced by osteoblasts, to RANK, the receptor on osteoclasts, leads to increased osteoclast differentiation, activation, and survival, resulting in increased bone resorption. OPG acts as a decoy receptor by binding with high affinity to RANKL therefore preventing the interaction with RANK. OPG thus acts as an effective inhibitor of bone resorption.

Many of the products of these processes can be measured as biochemical markers of bone turnover. Markers in current clinical use include, but are not limited to, degradation products of collagen I breakdown: telopeptides of the N-terminal (urinary NTx) and C-terminal (serum CTx) of collagen type 1; early markers of bone formation: N-terminal, N-terminal (urinary NTx) and C-terminal (serum CTx) of propeptide of type 1 collagen and bone-specific alkaline collagene type 1; and osteocalcin, a late marker of bone formation that appears only in the mineralization phase. Cathepsin K is also considered a marker of bone turnover.

In contrast to imaging techniques, biochemical markers of bone turnover obtained in serum samples show changes in a markedly larger range. Typically a decrease of 50%–80% or an increase of 100%–200% occurs in days or weeks of initiating treatment with antiresorptive or anabolic drugs compared with usual increases in BMD of 6%–7% with bisphosphonates and 2%–3% with SERMs after two years of therapy.

**Current pharmacologic treatments**

Pharmacologic therapies for osteoporosis are all recommended in the context of standard nonpharmacologic therapy including adequate calcium, vitamin D, and weight-bearing exercise. Calcium supplements are recommended for adults at doses of 1,000 mg daily until age 50 and 1,200 mg/day for adults over age 50 years. Concurrent vitamin D supplementation to ensure adequate calcium absorption is also recommended at doses of 800–1,000 international units (IU)/day for adults ages 50 and older, with the goal of achieving serum levels of at least 30 ng/mL. Assessment of vitamin D status is important, given that an estimated 77% of adults in the US are considered to have inadequate levels of vitamin D, ie, below 30 ng/mL. Sunlight exposure is important in maintaining adequate levels of vitamin D, causing production of the vitamin D3 prohormone through ultraviolet B irradiation of its 7-dehydrocholesterol precursor in the skin. However, even in latitudes where the sunlight intensity can facilitate this reaction year-round, insufficient levels of vitamin D are common in the population.

Although no formal recommendations for amounts of sun exposure exist, research referenced by the US National Institutes of Health has suggested that 5–30 minutes of exposure between 10 am and 3 pm at least two times a week without sunscreen may be adequate to maintain vitamin D levels. For patients who are vitamin D-deficient, replacement levels of oral vitamin D of 50,000 IU/week should be taken for 8–12 weeks and then at least 1,000 IU/day.

Exercise, including weight-bearing activities such as running, jumping, and resistance training, can also contribute to osteoporosis prevention. Specific recommendations for maintenance of bone health from organizations such as the US NOF and the American College of Sports Medicine include performance of weight-bearing exercise for a total of 30 minutes on most days and resistance training of 8–12 repetitions or 8–10 exercises at least two days a week. Common-sense fall prevention strategies also contribute to fracture prevention.

An osteoporosis medication may have an indication for prevention of osteoporosis in patients with low bone mass, treatment of patients with already established osteoporosis, or both (Table 1). To be approved for prevention of osteoporosis in patients in the US, agents must be shown in clinical trials to significantly increase BMD in patients with low bone mass. Therapies approved for treatment of already established osteoporosis must demonstrate a significant reduction in fractures.

Most currently approved drugs for osteoporosis prevention or treatment are antiresorptive (Table 1). The bisphosphonates, alendronate and risedronate, are often the first drugs recommended for treating postmenopausal osteoporosis. Bisphosphonates are approved for both
prevention and treatment. Indications for estrogen are limited to prevention, whereas the calcitonin and PTH analogs are reserved for treatment. PTH is the single anabolic agent currently available in the US. Its use is limited to treatment of osteoporosis for two-year periods.

The focus of the therapies presented here is the treatment and prevention of primary osteoporosis associated with menopause and aging. However, it should be noted that a number of other diseases, as well as drugs and nutritional deficiencies, can cause secondary osteoporosis, the most frequent being glucocorticoid excess. Other conditions associated with secondary osteoporosis include endocrine disorders such as Cushing’s syndrome, hypogonadism, and Type 1 diabetes mellitus; gastrointestinal disease including celiac disease and other malabsorption syndromes, and liver disorders; bone marrow-related conditions such as thalassemia and other anemias; and other miscellaneous causes including chronic obstructive pulmonary disease, multiple sclerosis, and rheumatoid arthritis. Among the numerous medications associated with osteoporosis are heparin, anticonvulsants such as phenytoin and phenobarbital, lithium, cancer chemotherapeutic agents, and excessive thyroid hormone.

Although patients with secondary osteoporosis can benefit from therapies used for primary osteoporosis, it is important to identify secondary osteoporosis because there are often effective specific interventions that can be added to the more general approach.

### Antiresorptive agents

#### Bisphosphonates

Bisphosphonates are the most commonly prescribed drugs used to treat osteoporosis in the US and many other countries. Etidronate was the first bisphosphonate to be used as therapy beginning in the 1960s. Although its approved indications in the US are limited to treatment of hypercalcemia and Paget’s disease, a disease of accelerated bone turnover, etidronate is commonly used in Europe and other countries for treatment of osteoporosis as cyclic oral therapy, given for two weeks every

<table>
<thead>
<tr>
<th>Drug</th>
<th>Prevention</th>
<th>Treatment</th>
<th>Spine</th>
<th>Hip</th>
<th>Other nonvertebral</th>
<th>Oral</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Nasal spray</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BISPHOSPHONATES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alendronate</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>5–10 mg daily</td>
<td>35–70 mg weekly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risedronate</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>5 mg daily</td>
<td>35 mg weekly</td>
<td>150 mg monthly</td>
<td></td>
</tr>
<tr>
<td>Ibandronate</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>2.5 mg daily</td>
<td>150 mg monthly</td>
<td>3 mg every</td>
<td></td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>5 mg once a year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ESTROGEN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lowest possible dose, eg, 0.3 mg CEE (plus 1.5 mg medroxyprogesterone acetate) daily to start</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjugated equine estrogen with or without progestin</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td>60 mg daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SYNTHETIC ESTROGEN RECEPTOR MODULATORS (SERMs):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raloxifene</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>60 mg daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HORMONE ANALOGS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmon calcitonin</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>25–100 IU daily</td>
<td>200 IU daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parathyroid hormone (teriparadise)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 ug daily</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
three months.\textsuperscript{29} Alendronate, a once daily oral medication, was the first bisphosphonate to be approved for treatment of osteoporosis in the US in 1995. Since that time, newer bisphosphonates with less frequent dosing intervals have been introduced, partially in an attempt to improve compliance. In addition to alendronate, three other bisphosphonates have been approved in the US for both treatment and prevention of osteoporosis. Risedronate is an oral medication that can be administered daily, weekly, or monthly at varying doses (Table 1). Zoledronic acid is medication administered once yearly by intravenous transfusion. Ibandronate is available in both oral and intravenous forms at various dosing frequencies.

Other bisphosphonates not approved in the US, but available in other countries for treatment of osteoporosis, include clodronate and pamidronate. Both are usually taken as oral agents, but are also available for intravenous, and in the case of clodronate, intramuscular administration.\textsuperscript{30}

Bisphosphonates are structurally related to inorganic pyrophosphate, a naturally occurring compound composed of two phosphate groups.\textsuperscript{31} Like pyrophosphate, bisphosphonates bind to hydroxyapatite crystals and thus have a very high affinity for bone. Upon exposure to acid and enzymes secreted by an active osteoclast, bisphosphonates are released from the bone matrix where they promote osteoclast apoptosis.\textsuperscript{31,32}

Bisphosphonates differ in strength of binding to the bone mineral matrix, with the zoledronic acid having the highest affinity followed by pamidronate > alendronate > ibandronate > risedronate > etidronate > clodronate.\textsuperscript{31,33} Higher-affinity bisphosphonates bind avidly to the bone surface, but spread through bone slowly. Lower-affinity agents are distributed more widely through the bone, but have a shorter residence time when treatment is stopped. Suppression of bone resorption occurs within approximately three months of initiation of oral bisphosphonate therapy regardless of dosing frequency, but is more rapid after intravenous administration. Length of suppression is largely a function of affinity for mineral matrix binding; zoledronic acid, with the highest affinity, effectively suppresses markers of bone turnover for up to one year.

Bisphosphonates in general have been shown to increase BMD of the spine by 5\textperthousand{}–8\textperthousand{} and at the hip by 3\textperthousand{}–6\textperthousand{} after three years. All bisphosphonates have been shown to reduce vertebral fractures by 40\textperthousand{}–70\textperthousand{}.\textsuperscript{32} Alendronate, risedronate, and zoledronic acid also reduced nonvertebral fractures by 25\textperthousand{}–40\textperthousand{}, including hip fractures by 40\textperthousand{}–60\textperthousand{}, in women with osteoporosis.\textsuperscript{32} Ibandronate has not been shown to reduce nonvertebral fractures.

Divalent cations from food or other ingested sources will completely block absorption of oral bisphosphonates. Therefore, these agents must be taken after a prolonged fast, followed by 30–60 minutes with nothing else by mouth. Even under these conditions, less than 1\textperthousand{} of an orally administered dose is absorbed. Bisphosphonates do not undergo systemic metabolism and their plasma half-lives are short. Fifty percent of the absorbed dose binds to bone surfaces; the other 50\textperthousand{} is excreted rapidly by the kidneys.\textsuperscript{32}

Because bisphosphonates accumulate in bone, they can be continued to be released from bone for months or years after treatment is stopped and may protect against fracture for 3–5 years after treatment is stopped.\textsuperscript{32} On this basis, consideration of a “drug holiday” after 5–10 years of bisphosphonate treatment has been advocated, with longer treatment periods and shorter off-treatment periods recommended for those at greatest risk of fracture.

Side effects of bisphosphonates include upper gastrointestinal symptoms and infrequent bone, joint, and/or muscle pain. Osteonecrosis of the jaw is another rare, but serious, side effect that was identified through post-marketing surveillance. According to a report of a task force of the American Society for Bone and Mineral Research, osteonecrosis of the jaw, formally defined as the presence of exposed bone in the maxillofacial region that does not heal within eight weeks of identification by a healthcare provider, was estimated to occur in between one in 10,000 to less than one in 100,000 patient years.\textsuperscript{34} A recent re-evaluation of three large, randomized controlled trials of bisphosphonates has shown no increase in “atypical” femoral shaft fractures, which had previously been suggested to be linked to their use.\textsuperscript{35}

**Estrogen**

Estrogen has long been used in the prevention of osteoporosis, with widespread use beginning in the 1980s when it was cited by a US National Institutes of Health Consensus Conference as the most effective means for preventing bone loss.\textsuperscript{36} Use of conjugated equine estrogen (CEE) in combination with progestins, to protect against adverse endometrial changes, continued to increase through the 1990s, so that by 2001 approximately 15 million women in the US aged 50–74 years were using estrogen therapy, with 42\textperthousand{} of women of that age estimated to have had some exposure to hormone replacement therapy.\textsuperscript{37}
Following release of results of the Women’s Health Initiative (WHI) in 2002 showing increased adverse events associated with estrogen therapy, its use declined rapidly worldwide.38−42 Although confirming the association of estrogen with decreases in biochemical markers of osteoporosis of 50%−60%, a two-year increase in BMD of 4%−6% in the hip and spine, and decreased incidence of both vertebral and hip fractures of 34% after five years, the trial was stopped three years early due to significantly increased risks of coronary heart disease, stroke, pulmonary embolism, and breast cancer in estrogen/progestin users compared with the placebo group.43 A year and a half later, the estrogen-only arm in post-menopausal women with hysterectomy was also stopped early due to increased incidence of stroke.44

Estrogen therapy is now recommended for osteoporosis prevention only in patients with significant risk of osteoporosis and only after all nonestrogen medication has been carefully considered. The recommended starting dose is 0.3 mg CEE (plus 1.5 mg medroxyprogesterone acetate). Currently no estrogen (or progestin) product has a Food and Drug Administration (FDA) indication for treatment of osteoporosis.45

SERMs
SERMs represent a growing number of compounds that act as either estrogen receptor agonists or antagonists in a tissue-specific manner. They are a chemically diverse group that lack the steroid structure of estrogen, but possess a tertiary structure that allows them to bind to estrogen receptors ER-alpha and/or ER-beta. The goal is to develop SERMs that dissociate the favorable estrogenic effects on bone and the cardiovascular system from unfavorable stimulatory effects associated with breast and endometrial cancer.

Currently there are two main chemical classes of SERMs approved for clinical use: triphenyl ethylene derivatives (tamoxifen and toremifene which are used to treat breast cancer) and benzothiopene derivatives (such as raloxifene, the only SERM currently indicated for the prevention and treatment of osteoporosis in the US). In 2007, raloxifene was also granted an indication for breast cancer prevention by the FDA.

Raloxifene is an oral medication given in a dose of 60 mg/day. Four major international trials have assessed the use of raloxifene in 37,000 postmenopausal women.46 In two osteoporosis prevention trials47,48 and two treatment trials of women with postmenopausal osteoporosis,49,50 raloxifene use has been associated with a 30% reduction in biochemical markers of osteoporosis, three-year increases in BMD of 2% and 3% at the hip and spine and decreased vertebral fractures by 30%–50% in women with pre-existing vertebral fractures or low bone density. It has not been shown to have a significant effect on nonvertebral or hip fractures. Raloxifene is associated with hormonally related side effects such as increased risk of blood clots and vasomotor symptoms, including hot flushes.

Two newer SERMs that have recently received approval in Europe, but are not yet approved in the US, are lasofoxifene and bazedoxifene (Table 2). Lasofoxifene is a third generation naphthalene derivative SERM that binds to both ERα and ERβ with high affinity. Its half-life is two times longer than that of raloxifene and it has better oral bioavailability.51 Lasofoxifene has been tested in 17 Phase II/III trials involving more than 10,000 women for postmenopausal osteoporosis.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect</th>
<th>Mechanism of action</th>
<th>Dosing</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strontium ranelate</td>
<td>Anabolic and antiresorptive</td>
<td>Calcium-like atom; stimulates osteoblasts and inhibits osteoclasts</td>
<td>Oral</td>
<td>Approved in Europe since 2004; Related compound, strontium malonate, in clinical trials in US</td>
</tr>
<tr>
<td>Odanacatib</td>
<td>Antiresorptive</td>
<td>Cathepsin K inhibitor</td>
<td>Oral</td>
<td>In Phase III trials in the US</td>
</tr>
<tr>
<td>Ostabilin-C</td>
<td>Anabolic</td>
<td>Parathyroid hormone analog; stimulates osteoblasts via PTH receptor-1</td>
<td>Subcutaneous</td>
<td>In Phase III trials in the US</td>
</tr>
<tr>
<td>Lasofoxifene</td>
<td>Antiresorptive</td>
<td>SERM</td>
<td>Oral</td>
<td>Approved in Europe since 2009; in Phase III trials in the US</td>
</tr>
<tr>
<td>Bazedoxifene</td>
<td>Antiresorptive</td>
<td>SERM</td>
<td>Oral</td>
<td>Approved in Europe since 2009; in Phase III trials in the US</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Antiresorptive</td>
<td>Anti-RANKL monoclonal antibody</td>
<td>Subcutaneous</td>
<td>Approval in US and Europe expected in 2010</td>
</tr>
</tbody>
</table>
prevention or treatment, with key evidence coming from two large Phase III trials. In the Osteoporosis Prevention and Lipid Lowering study involving 1,907 women, increases in lumbar BMD of 2.3% were observed among those receiving lasofoxifene 0.25 or 0.5 mg/day, compared with a 0.7% reduction in patients who received placebo. The Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial demonstrated a reduction in vertebral fractures of 42% after three years and nonvertebral fractures, primarily forearm and wrist, of 24% among women with osteoporosis after five years of treatment. Rates of venous thromboembolism were also significantly increased. Based on earlier data from the PEARL trial, an FDA application for lasofoxifene was submitted in September 2008. Approval is currently pending a response to a request for additional information. Lasofoxifene 0.5 mg/day was approved for treatment of osteoporosis by the European Medicines Agency in April 2009.

Bazedoxifene is another third generation SERM currently undergoing investigation in clinical trials. It is based on a raloxifene template with an indole ring substituting for the benzothioprine core. In clinical trials of postmenopausal women with osteopenia, bazedoxifene 20 mg/day and 40 mg/day resulted in increases in BMD at the lumbar spine and other sites of approximately 1.5% and was associated with significant decreases in markers of bone turnover. In Phase III trials, bazedoxifene in doses of 20 mg/day or 40 mg/day was associated with reduction of vertebral fractures of 39% and a nonsignificant reduction of all fractures of 16% over three years. Among women at high risk of fracture in the next 10 years (22%) based on FRAX® additive effect with estrogen on bone.59 Results from a recent study of bazedoxifene-based TSECs showed the combination in markers of bone turnover compared with raloxifene at most doses.58

Problems with side effects and demonstrating efficacy in reducing fractures has prevented other SERMs, such as tibolone and arzoxifene, from continuing toward approval. A number of other SERMs continue to be developed and await completion of testing in clinical trials.

Calcitonin
Calcitonin is another antiresorptive agent approved for treatment of osteoporosis. Like the endogenous form of the hormone, it acts on the calcitonin receptor on osteoclasts to decrease their activity. Of the many synthetic or recombinant calcitonins from different species that have been used for medical purposes, including human calcitonin, porcine calcitonin, eel calcitonin-derivative, and salmon calcitonin, the salmon preparation (SCT) is the most widely used in clinical practice.

SCT is available as an injectable formulation for intravenous, intramuscular or subcutaneous use, and as a nasal spray. Injectable SCT was the first to be introduced and was approved in the US in 1984 and is available in 90 other countries for osteoporosis treatment. SCT was approved as a nasal spray for treatment of postmenopausal osteoporosis in the US in 1995 and is currently the most commonly used calcitonin formulation, in part due to its convenience of administration. Clinical trials of SCT nasal spray, taken at a dose of 200 IU/day, have demonstrated a 20% decrease in biomarkers of osteoporosis, a small effect on BMD in the spine (1%–2% increase), but a 36% reduced incidence of vertebral fractures in women with pre-existing vertebral fractures. No consistent effect on nonvertebral or hip fractures has been demonstrated. An oral SCT preparation is currently in development for clinical use.

Anabolic agents

**PTH**
A PTH analog is the only anabolic agent currently approved for treatment of osteoporosis in the US where it is available in the form of human recombinant PTH peptide 1–34 (teriparatide), a fragment of PTH that has a similar affinity for PTH receptor-1. An additional form, rhPTH1–84, which is identical to the endogenous full length PTH in humans, is currently available in Europe.

Although physiologically PTH is released in response to low serum calcium and acts to mobilize calcium from the bone, pharmacologically, when given intermittently
at low doses, it has been shown to have predominantly anabolic effects on osteoblasts. As indicated by markers of bone turnover, PTH initiates bone formation first and only later promotes bone resorption, resulting in an “anabolic window” of approximately 18–24 months in duration.67

The recommended dose of teriparatide is 20 µg/day; given as a subcutaneous injection with a modified insulin pen. In clinical trials overall, teriparatide was shown to: increase BMD at both the spine, up to 10%, and femur, to a lesser degree; and decrease vertebral fractures by about 65% and nonvertebral fractures by about 35%.68,69 Because its effects on BMD have not been consistent across trials, teriparatide is only approved for osteoporosis treatment and not prevention. Because the long-term safety and efficacy are not known, PTH can be prescribed for no more than 24 months. It is contraindicated in patients with hyperparathyroidism, hypercalcemia, or at risk of osteosarcoma, including those with unexplained high alkaline phosphatase levels, Paget’s disease, or who have undergone irradiation on the bones.67

Strontium ranelate

Strontium ranelate is an oral agent that has been approved for use in osteoporosis treatment in European countries since 2004. It is not approved in the US, but a related compound, strontium monolate, has FDA investigational new drug status. Strontium ranelate consists of two atoms of strontium and an organic moiety (ranelic acid) which dissociates in the digestive tract. Like calcium, strontium is a cation that is incorporated into the crystal structure of bone.

Strontium ranelate acts by both stimulating bone formation and decreasing bone resorption. In vitro, strontium ranelate has been shown to increase osteoblastic activity, including increasing collagen synthesis and modulating the OPG/RANKL system in favor of OPG, as well as decrease bone resorption by decreasing osteoclast differentiation and resorbing activity, and increasing osteoclast apoptosis.70 However, in vivo, some evidence suggests bone formation is favored with nonsignificant effects on bone resorption.71

In a summary of the results of four clinical trials of strontium ranelate, three for treatment of osteoporosis72–74 and one for prevention,75 2 g/day of strontium ranelate resulted in increased BMD at all sites, a 37% reduction in vertebral fractures and a 14% reduction in nonvertebral fractures over three years.71 As a result, the treatment received a “silver level of evidence” for reducing vertebral, and to a lesser degree nonvertebral, fractures in postmenopausal women from the Cochrane Collaboration.71 More recently, a five-year follow-up of one of the treatment trials demonstrated a 43% reduction in hip fractures and 24% reduction in vertebral fractures.76

New agents

New PTH analogs

Ostabolin-C is a cyclic 31-amino acid analog of PTH that activates the same PTH1 Type receptor activated by the other currently available PTH analogs.77 Unlike the current PTH analogs, however, ostabolin-C stimulates adenylyl cyclase alone and not in combination phospholipase C. These modifications are expected to limit its side effects.78 In a Phase II trial, daily subcutaneous injections of ostabolin-C in postmenopausal women with osteoporosis resulted in an increase in spine BMD of up to 5% after four months as reported by the drug’s manufacturer.79 Episodes of hypercalcemia were more frequent than in the placebo group only at the highest doses. Phase III trials of the injectable medication are now ongoing and a nasal spray preparation is under development.79

New agents with new targets

Denosumab is a human monoclonal antibody that binds to RANKL, the principal mediator of osteoclastic bone resorption (Figure 2). By inhibiting the action of RANKL, denosumab causes a reduction in the differentiation, activity, and survival of osteoclasts, leading to lower rates of bone resorption.80 It is given subcutaneously at a dose of 60 mg every six months. Denosumab has been proposed to have several advantages over bisphosphonate therapy, including the potential for increased compliance due to less frequent and easier administration (subcutaneous injection vs intravenous for zoledronic acid) with potentially fewer side effects.81

In the recently reported Phase III FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every six Months) trial of 7,868 women ages of 60–90 years with T-scores of −4.0 to −2.5 at the lumbar spine or total hip, subjects receiving denosumab had a significant reduction in vertebral fracture of 68%, in hip fracture of 40%, and in other nonvertebral fracture of 20% compared to those receiving placebo after three years.82

In August 2009, the drug received FDA fast-track status for treatment of osteoporosis. Final approval was delayed in October 2009, pending additional information on the proposed post-marketing surveillance program and updated safety data. The information was provided in January 2010 and approval...
is expected in July 2010.\textsuperscript{83} Denosumab received a positive opinion from the European Medicines Agency in December 2009, with final approval also expected in 2010.\textsuperscript{84}

Odanacatib is an orally administered inhibitor of cathepsin K being developed for treatment of osteoporosis and bone metastases. As described above, cathepsin K is the major collagenase secreted by osteoclasts to degrade the organic bone matrix during the bone remodeling process (Figure 2). In a recently reported Phase II clinical trial in postmenopausal women with osteoporosis, 24 months of treatment with odanacatib 50 mg/week produced increases in BMD of 5.5% at the spine and 3.2% at the hip.\textsuperscript{85} Side effects appeared to be minimal, in contrast to earlier trials of another cathepsin K inhibitor that had been associated with skin problems including sclerosis.\textsuperscript{86} Phase III trials of odanacatib that will involve up to 20,000 women are ongoing.

**Emerging therapies**

New discoveries related to pathways regulating osteoblast and osteoclast function are leading to the development of new drugs with novel targets. The Wnt/\(\beta\)-catenin pathway that regulates gene transcription of proteins important for osteoblast function is one such target (Figure 3). Wnt signaling is activated by one of 19 secreted Wnt proteins binding to one of 10 frizzled receptors, initiating a signaling cascade which results in the release of \(\beta\)-catenin from a complex containing glycogen synthase kinase 3\(\beta\) (GSK3\(\beta\)), and its subsequent accumulation and translocation into the nucleus. \(\beta\)-catenin then binds with the transcription factor tcf/lef and initiates target gene transcription that leads to increased bone formation.\textsuperscript{87}

The first clues of the importance of the pathway in bone regulation were studies showing specific mutations of the gene for a Wnt receptor, lipoprotein receptor-like protein 5 (LRP5), were involved in syndromes of osteoporosis (osteoporosis pseudoglioma); other mutations of the same gene were subsequently associated with high bone mass. LRP5 is a co-receptor along with the frizzled receptors for Wnt proteins. Study of the pathway has led to further discovery of inhibitors of Wnt signaling secreted by osteocytes. These include sclerostin and dickkopf 1 protein (DKK1), both of which block binding of Wnt to LRP5 (or the related LRP6 receptor), thereby inhibiting osteoblast stimulation. Sclerostin is the protein product of the SOST gene, mutations of which cause sclerosing bone diseases.\textsuperscript{88,89} Decreased sclerostin secretion has been implicated as the signal for increasing Wnt pathway activity in mechanical stimulation of bone.\textsuperscript{90}

Monoclonal antibodies designed to block the inhibiting action of both sclerostin and DKK1 are being considered for clinical trials based on promising results in animal
Because both of these molecules appear to be secreted only by bone, it is hoped that they will have fewer systemic adverse effects than other Wnt pathway-related therapies. Therapies targeted at other molecules in the pathway, for example a small molecule inhibitor of GSK3β, the enzyme which causes degradation of β-catenin in the absence of Wnt signaling, are considered less desirable targets due to their action in many tissues in addition to bone.

Therapies being developed based on other targets include calcium receptor antagonists that stimulate transient release of PTH from the parathyroid gland. Bone morphogenetic proteins, growth factors belonging to TGF-β superfamily and involved in a multitude of processes including embryonic and post natal development, are potent bone inducers being used in clinical studies for local fracture healing. Their potential for treatment in osteoporosis is also being explored.

Conclusion

Many new agents for osteoporosis therapy are currently in the development pipeline. Several of these agents, including denosumab, a monoclonal antibody that blocks the actions of the collagenase cathepsin K, are nearing US FDA approval. Further elucidation of the role of Wnt signaling and other pathways in osteoblasts promises to add more treatment options in the coming decade, with a greater emphasis on anabolic agents. These agents may also be useful in combination with existing antiresorptive agents, further expanding therapeutic options in the future.

Acknowledgment

This is manuscript 20746-MEM. The work was supported by a grant from the National Institutes of Health AR054901-01A2.

Disclosure

The author reports no conflicts of interest in this work.

References


